Resolve Medical launches IntractMD to flag supplement-related medication risks

Resolve Medical says its new IntractMD platform can help health plans, pharmacy benefit managers, health systems and pharmacists spot interactions involving prescriptions, supplements, vitamins and foods as Medicare puts more weight on medication safety. The launch comes as CMS expands Comprehensive Medication Review eligibility and begins measuring new Part D quality metrics that increase scrutiny of polypharmacy risk.

Why it matters: - Medicare’s 2027 Star Ratings will include new Part D quality measures tied to medication safety in older adults. - CMS has also expanded eligibility for annual Comprehensive Medication Reviews, nearly doubling the number of beneficiaries who can receive them. - That combination increases the number of reviews and raises the stakes for finding every product a patient uses, including supplements and over-the-counter medicines.

What happened: - Resolve Medical, LLC announced IntractMD™, a patent-pending four-surface platform designed to identify interactions involving prescriptions, dietary supplements, vitamins and foods in a single workflow. - The platform is aimed at health plans, pharmacy benefit managers, health systems and pharmacy organizations. - The company said the platform is available at Resolve Medical.

The details: - CMS expanded Part D Medication Therapy Management eligibility on January 1, 2025, increasing annual Comprehensive Medication Review eligibility from about 3.6 million to roughly 7.1 million beneficiaries. - CMS is already calculating performance for two Pharmacy Quality Alliance measures that will affect 2027 Medicare Star Ratings: Concurrent Use of Opioids and Benzodiazepines and Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults. - Those ratings are based on 2025 measurement-year data, so organizations are already being evaluated. - The MTM Program Completion Rate for Comprehensive Medication Review moves to the CMS Display Page for the 2025 and 2026 measurement years before returning as a Star Ratings measure in the 2029 ratings using 2027 performance data. - CMS defines a Comprehensive Medication Review as an annual review of a beneficiary’s complete medication regimen, including prescription medications, over-the-counter medications, herbal products and dietary supplements. - Prescription claims and electronic health records usually capture prescription drugs, but supplements, vitamins and many over-the-counter products often do not. - Resolve Medical says pharmacists therefore rely heavily on patient recall when reviewing non-prescription products. - The company said common over-the-counter allergy medications can add to anticholinergic burden even when they do not appear in prescription records. - Tom Lash, founder of Resolve Medical, said existing drug-interaction tools usually cover prescription drugs but do not consistently capture the supplement layer. - Lash said IntractMD is built to fit existing pharmacy workflows and can look different for the pharmacist in the encounter, the case manager working a panel or the plan reviewing a population. - IntractMD screens prescriptions together with dietary supplements, vitamins and foods in one query. - The platform produces a Composite Polypharmacy Risk Score across eight clinical dimensions, including bleeding risk, cardiac risk, central nervous system effects, CYP450 interactions and renal and hepatic considerations. - The knowledge base includes more than 173,000 drug-pair analyses covering about 590 commonly prescribed U.S. medications. - Drug terminology is standardized using RxNorm, and the interaction content is grounded in FDA-approved prescribing information. - Results are available in English and Spanish and can be shared directly with patients after a medication review. - Resolve Medical offers four connected applications: a patient-facing interaction checker, a population-screening engine, a clinical workflow application for MTM pharmacists and case managers, and a deprescribing review application in pilot preview. - The deprescribing tool identifies medications that appear in published deprescribing criteria and links users to original clinical sources. - The patient-facing application is publicly available at IntractMD. - Institutional applications are available through pilot programs at Resolve Medical. - The company says IntractMD is an analytics and clinical decision-support information platform and does not complete Comprehensive Medication Reviews, determine CMS measure performance or establish payment eligibility. - Clinical decisions remain the responsibility of licensed healthcare professionals.

Between the lines: - Medicare’s shift toward broader medication-safety measurement makes non-prescription products harder for organizations to ignore. - The biggest operational gap is not detecting prescription interactions. It is capturing the supplement and OTC layer quickly enough during real-world workflows. - Resolve Medical is positioning IntractMD as a workflow tool rather than a stand-alone database, which suggests the company is targeting adoption inside existing MTM and population-review processes.

What's next: - Resolve Medical is offering qualified health plans, pharmacy benefit managers, health systems and pharmacy organizations a no-cost 60-day pilot. - The pilot runs on the company’s cloud infrastructure and does not require software installation or IT integration to begin. - Organizations evaluating Star Ratings exposure in 2025 and 2026 will likely be watching whether the platform can help surface hidden medication risks before the 2027 measures take hold.

The bottom line: - Resolve Medical is betting that Medicare’s expanding focus on medication safety will create demand for tools that can uncover supplement and OTC risks that prescription-only systems miss.